REFERENCES
- Krantz MJ, Mehler PS. Treating opioid dependence: Growing implications for primary care. Arch Intern Med 2004; 164(3):277–288.
- Marsch LA. The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior and criminality: A meta-analysis. Addiction 1998; 93(4):515–532.
- Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev 2003; (2):CD002209.
- Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2008; (2):CD002207.
- Mark TL, Woody GE, Juday T, Kleber HD. The economic costs of heroin addiction in the United States. Drug Alcohol Depend 2001; 61(2):195–206.
- Barnett PG. Comparison of costs and utilization among buprenorphine and methadone patients. Addiction 2009; 104(6):982–992.
- National Consensus Development Panel on Effective Medical Treatment of Opiate Addiction. Effective medical treatment of opiate addiction. JAMA 1998; 280(22):1936–1943.
- Gordon AJ, Trafton JA, Saxon AJ, Gifford AL, Goodman F, Calabrese VS, McNicholas L, Liberto J. Implementation of buprenorphine in the Veterans Health Administration: Results of the first 3 years. Drug Alcohol Depend 2007; 90:292–296.
- Department of Veterans Affairs. Veterans Health Administration. Uniform Mental Health Services in VA Medical Centers and Clinics. VHA Handbook 1160.01. September 11, 2008. Accessed on November 14, 2012.
- Arfken CL, Johanson CE, di Menza S, Schuster CR. Expanding treatment capacity for opioid dependence with office-based treatment with buprenorphine: National surveys of physicians. J Subst Abuse Treat 2010; 39(2):96–104.
- Ducharme L, Abraham A. State policy influence on the early diffusion of buprenorphine in community treatment programs. Subst Abuse Treat Prev Policy 2008; 3(1):17–27.
- Knudsen HK, Ducharme LJ, Roman PM. Early buprenorphine adoption in substance abuse treatment centers: Data from the public and private sectors. J Subst Abuse Treat 2006; 30:363–373.
- Knudsen HK, Ducharme LJ, Roman PM. The adoption of medications in substance abuse treatment: Associations with organizational characteristics and technology clusters. Drug Alcohol Depend 2007; 87(2–3):164–174.
- Koch AL, Arfken CL, Schuster CR. Characteristics of US substance abuse treatment facilities adopting buprenorphine in its initial stage of availability. Drug Alcohol Depend 2006; 83:274–278.
- Ling W, Jacobs P, Hillhouse M, Hasson A, Thomas C, Freese T, Sparenborg S, McCarty D, Weiss R, Saxon A, Cohen A, Straus M, Brigham G, Liu D, McLaughlin P, Tai B. From research to the real world: Buprenorphine in the decade of the Clinical Trials Network. J Subst Abuse Treat 2010; 38(Suppl. 1):S53–S60.
- Roman PM, Abraham AJ, Knudsen HK. Using medication-assisted treatment for substance use disorders: Evidence of barriers and facilitators of implementation. Addict Behav 2011; 36(6):584–589.
- Stein BD, Gordon AJ, Sorbero M, Dick AW, Schuster J, Farmer C. The impact of buprenorphine on treatment of opioid dependence in a Medicaid population: Recent service utilization trends in the use of buprenorphine and methadone. Drug Alcohol Depend 2012; 123(1-3):72–8.
- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. (4th ed.). Washington, DC: American Psychiatric Association, 1995.
- Baxter JD, Clark RE, Samnaliev M, Leung GY, Hashemi L. Factors associated with Medicaid patients’ access to buprenorphine treatment. J Subst Abuse Treat 2011; 41(1):88–96.
- Substance Abuse and Mental Health Services Administration. Results from the 2005 National Survey on Drug Use and Health: Detailed Tables. Rockville, MD: Center for Behavioral Health Statistics and Quality, 2006.
- Substance Abuse and Mental Health Services Administration. Results from the 2010 National Survey on Drug Use and Health: Detailed Tables. Rockville, MD: Center for Behavioral Health Statistics and Quality, 2012.